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Tonic inhibitory GABAA receptor-mediated currents are observed in numerous cell types in the CNS, including thalamocortical neurons
of the ventrobasal thalamus, dentate gyrus granule cells, and cerebellar granule cells. Here we show that in rat brain slices, activation of
postsynaptic GABAB receptors enhances the magnitude of the tonic GABAA current recorded in these cell types via a pathway involving
Gi/o G proteins, adenylate cyclase, and cAMP-dependent protein kinase. Using a combination of pharmacology and knockout mice, we
show that this pathway is independent of potassium channels or GABA transporters. Furthermore, the enhancement in tonic current is
sufficient to significantly alter the excitability of thalamocortical neurons. These results demonstrate for the first time a postsynaptic
crosstalk between GABAB and GABAA receptors.
Introduction
The action of GABA upon postsynaptic GABAA receptors can be
categorized into two general forms, namely phasic and tonic in-
hibition. Phasic inhibition is the short-lasting increase in synaptic
inhibitory conductance generated in response to vesicular release
of GABA. Tonic inhibition, on the other hand, is produced via
activation of high affinity receptors by ambient GABA (Farrant
and Nusser, 2005).
GABAA receptor-mediated tonic inhibition plays a diverse
and important role in CNS function. For example, the level of
tonic inhibition modifies synaptic integration in cerebellum
(Chadderton et al., 2004), regulates anxiety-related behaviors
and seizure susceptibility in the dentate gyrus (Maguire et al.,
2005), and is necessary for the expressions of spike and wave
discharges in thalamocortical networks that are associated with
typical absence epilepsy (Cope et al., 2009).
It is well established that presynaptic GABAB receptors regu-
late the release of GABA. Furthermore, postsynaptic GABAB re-
ceptors produce a slow IPSP resulting from the activation of G
protein-coupled, inwardly rectifying potassium (GIRK) channels
(Bowery et al., 2002). However, here we show for the first time
that GABAB receptors can also regulate tonic inhibitory tone by
modulating GABAA receptors via a postsynaptic mechanism.
Materials andMethods
Whole-cell voltage clamp. Wistar rats, B6.129-Gabrd tm1Geh/J ( knock
out, /) mice and BALB/c-Gabab1 tm1Bbe (GABAB knockout,
GABAB
/)mice (postnatal days 20–30, of either sex)were anesthetized
with isoflurane and decapitated in accordance with the United Kingdom
Animals (Scientific Procedures) Act of 1986 and local ethical committee
approval. As described previously (Cope et al., 2005), brains were rapidly
removed and 300 m-thick horizontal ventrobasal (VB) thalamus and
dentate gyrus and coronal (cerebellum) slices were cut in continuously
oxygenated neuroprotective sucrose aCSF. Slices were incubated for at
least 1 h before being transferred to the recording chamber where they
were continuously perfused (2 ml/min) with warmed (32–34°C) oxy-
genated recording aCSF containing the following (in mM) 125 NaCl,2,5
KCl, 25 NaHCO3, 1.25 NaH2PO4, 1 MgCl2, 2 CaCl2, 25 glucose, 3
kynurenic acid, and 0.0005 tetrodotoxin. Neurons were visualized using
a Nikon Eclipse E600FNmicroscope equipped with a 40 or 60 immer-
sion lens and a video camera (Hamamatsu. Whole-cell patch-clamp re-
cordings were made from neurons held at 70 mV using pipettes
(resistance, 2–4 M) containing the following (in mM): 130 CsCl, 2
MgCl2, 4Mg-ATP, 0.3 Na-GTP, 10 Na-HEPES, and 0.1 EGTA, pH 7.25–
7.30 (osmolality, 295 mOsm). Gramicidin-perforated patch record-
ings were performed as described by Connelly and Lees (2010). To
calculate the reversal potential, the gabazine-sensitive current was fit
with a Goldman–Hodgkin–Katz flux equation (Hille, 2001). Voltage
clamp was performed with a Multiclamp 700B preamplifier (Molecular
Devices). Series resistance was compensated by 70–80% and was moni-
tored regularly during recordings. Data were discarded if the series resis-
tance was over 20 M or changed by 20%. Experimental data were
filtered at 3–6 kHz, digitized at 20 kHz (Digidata 1322A; Molecular
Devices), and acquired using pClamp 10 software (Molecular Devices).
Only a single experiment was performed on each slice, after which the
slice was discarded. For experiments involving the infusion of intracel-
lular G-protein signaling modulators/blockers, four neurons were
patched simultaneously. Two neurons were selected and patched with
drug-containing intracellular solution, while two were patched with
drug-free solution to serve as the control. All drugs and reagents used
were obtained from Sigma-Aldrich, Tocris Bioscience, or Abcam.
Dynamic clamp. Dynamic clamp was performed using the CED
Power1401 system. The frequency component of the tonic current was
calculated by subtracting the power spectrumof thewhole-cell current in
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the presence of gabazine from the control power spectrum. These data
could be fit with the sum of two functions (a high-frequency and low-
frequency component) given by S( f ) 2D 2/(1 (2 f)2). The vari-
ables D and  were used to create a noisy conductance based on an
Ornstein–Uhlenbeck process such that the noise generated had the same
power spectrum as that experimentallymeasured. The injected noise was
generated by the equation dGt/dt (Gbase Gt)/D where Gt is
the conductance at any given sample, Gbase is the mean conductance
value of the tonic conductance, and  is a random value obeying Gauss-
ian statistics with amean of 0 and standard deviation of 1 (Destexhe et al.,
2001). D and  for the high and low-frequency components were calcu-
lated across 20 cells, and an average was generated. Thus, to mimic the
basal tonic current,Gbase 1.4 nS,D1 0.06 nS
2, 1 10.2ms,D2 1.8
nS2, and 2 0.51ms. Tomimic the baclofen-enhanced tonic current, the
values wereGbase 2.0 nS,D1 0.12 nS
2, andD2 3.6 nS
2, while 1 and
2 were not changed. Excitatory postsynaptic
conductances had a 10–90% rise time of 2 ms
and a decay time constant of 10 ms to mimic
corticothalamic input (Hsu et al., 2010). I/O
curves generated from dynamic clamp data
were fit with amodified Boltzmann curve, with
the equation P(G)  1/(1  exp((E  G)/S)),
where, P(G) is the probability of firing an action
potential at EPSP conductanceG. E is the EG50,
that is, the excitatory conductance where cells
fire an action potential on 50%of trials, and S is
the slope of the curve at the EG50.
Data analysis. To measure the amplitude of
the tonic current, an all points histogram was
constructed for pre-gabazine and post-
gabazine application, and the size of the tonic
current was calculated as the difference be-
tween the modes. The magnitude of the tonic
current did not correlate with whole-cell ca-
pacitance (p 0.8, Pearson’s test), so it was not
adjusted for capacitance. Across our dataset,
the magnitude of the tonic current in control
conditions was not normally distributed (p 	
0.0001, n  51; D’Agostini test); however, the
logarithm of the data was Gaussian (p 0.15).
Furthermore, manipulations that altered the
magnitude of the tonic current also altered the
variance of the sample (e.g., across all VB neu-
rons, the tonic current had a standard devia-
tion of 69 pA, but in the presence of CGP this
dropped to 24 pA; F(50, 38) 7.2, p	 0.0001).
However, after taking the logarithm of the data,
homoscedasticity was preserved (F(50,38)  1,
p  0.9). Therefore, we took the log10 of all
tonic currents and then subjected them to an
unpaired Student’s t test or ANOVA that, if
significant, was followed up with a Dunnett’s
post-test. Data are presented as mean
 SEM.
Significance was set at p	 0.05 for all statistical
tests.
Results
In the presence of TTX (500 nM) to mini-
mize any potential presynaptic effect of
drugs, application of the GABAA receptor
antagonist gabazine to the recording bath
(100 M) revealed a tonic GABAA-
mediated current in rat thalamocortical
(TC) cells, dentate gyrus granule cells
(DGGCs), and cerebellar granule cells
(CGCs) (TC: 104
 5 pA, n 21; DGGC:
14
 2 pA, n 11; CGC: 12
 1 pA, n
7) (Fig. 1A). Application of the GABAB
receptor agonist R-baclofen (5 M) for 5 min before gabazine
addition significantly enhanced the tonic current (TC: 160
 13
pA,n 11;DGGC: 21
 2 pA,n 13; CGC: 28
 3 pAn 7; p	
0.05, Dunnett’s post-test) (Fig. 1A). This enhancement could be
blocked by the simultaneous application of the GABAB receptor
antagonist CGP 55845 (1 M). Furthermore, in line with pub-
lished findings (Cope et al., 2009), concurrent application ofCGP
55845 with baclofen reduced the tonic current to below control
levels, indicating a basal level of activity in this pathway in our
slices (TC: 69
 6 pA, n 11; DGGC: 6
 2, n 6; CGC: 6
 1,
n 7; p	 0.001, Dunnett’s post-test; Fig. 1A). A concentration–
response curve toR-baclofen showed that the EC50 for enhancing
the tonic current in TC cells was 1.8 
 0.2 M, similar to that
A
B C
Figure 1. GABAB receptor activation increases themagnitude of the tonic GABAA current. A, Application of baclofen to activate
GABAB receptors enhances the magnitude of the tonic current recorded in thalamocortical, dentate gyrus, and cerebellar granule
cells. Application of the GABAB antagonist CGP 55845 reduced the tonic current below control levels. B, Dose–response curve of
baclofen enhancement of on tonic current in thalamocortical neurons. C, The weak GABAB agonist GHB also enhances the tonic
current in thalamocortical neurons.
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reported for other neuronal actions of
R-baclofen in vitro (Newberry and
Nicoll, 1985) (Fig. 1B). The weak GABAB
receptor agonist –hydroxybutyrate
(GHB; 3 mM) enhanced the tonic current
in TC cells by a similar magnitude (con-
trol: 105
 6 pA; GHB: 175
 10 pA; n
11, p	 0.0001, t test) (Fig. 1C). To inves-
tigate whether the GABAB-mediated en-
hancement was specific to the
extrasynaptic receptors that mediate the
tonic current, we also investigated
whether synaptic currents were altered by
measuring miniature inhibitory postsyn-
aptic currents (mIPSCs) in TC neurons.
Baclofen had no effect on the amplitude
or weighted decay of mIPSCs (control:
44 
 1 pA, 2.4 
 0.l ms; baclofen:
45
 1 pA, 2.3
 0.2 ms; p 0.05, Kol-
mogorov–Smirnov test), although it did
reduce their frequency (control: 3.4
 0.5
Hz; baclofen: 1.6
 0.3 Hz; p	 0.05, Kol-
mogorov–Smirnov test; data not shown).
This demonstrates the well established
fact that baclofen can presynaptically reg-
ulate GABA release while having no effect
on synaptic GABAA receptors (e.g., Le
Feuvre et al., 1997).
We further confirmed that baclofen was acting through
GABAB receptors by using knockoutmice (GABAB
/). In wild-
type littermate animals, baclofen still significantly enhanced the
tonic current (control: 64
 14 pA; baclofen: 146
 41 pA; n 8,
p  0.007, t test) (Fig. 2A). However, baclofen had no effect on
GABAB
/mice (control: 82
 14 pA; baclofen: 66
 17 pA; n
8–12, p  0.4, t test). Interestingly, it did not appear that
GABAB
/ mice had smaller tonic currents under control con-
ditions compared to wild-type animals, indicating a potential
upregulation in extrasynaptic GABAA receptor function to com-
pensate for the loss of the GABAB receptor function (p  0.5, t
test)(Fig. 2A).
To confirm that the baclofen-induced increase in tonic cur-
rent required expression of functional -containing GABAA re-
ceptors, we used -subunit knockout (/)mice. /mice did
not showabaclofen-induced enhancement in tonic current (con-
trol: 5
 7 pA; baclofen: 1
 3 pA; n 7–8, p 0.3, t test) (Fig.
2B). We next began to explore the possible mechanisms that may
underpin the effect of GABAB receptor activation on tonic cur-
rents. It is established that inhibiting GABA transporter (GAT)
function can alter the magnitude of tonic current (Nusser and
Mody, 2002) and that GABAB receptors can modulate the func-
tion of GATs (Gomeza et al., 1994). Therefore, we applied satu-
rating concentrations of NO-711 (10 M) and SNAP 5114 (20
M) to block the activity of GAT-1 and GAT-3 (the only GAT
subtypes present in the VB thalamus; De Biasi et al., 1998). How-
ever, when the activity of GABA transporters was removed,
baclofen still produced significant enhancement of the tonic cur-
rent (control: 117
 10 pA; baclofen: 193
 17 pA; n 9–10, p
0.001, t test)(Fig. 2C). Another classical action of GABAB recep-
tors is the activation of GIRK potassium channels. To exclude
the possibility that GIRK activation was responsible for the
GABABR-mediated enhanced tonic current, we applied a cock-
tail of potassium channel blockers including Ba2 (2 mM), 4-AP
(2 mM), and tetraethylammonium (TEA) (10 mM) to compli-
ment the intracellular block provided by our Cs-containing
pipette solution. However, in the presence of this range of potas-
sium channel blockers, baclofen still produced an enhancement
in tonic current amplitude (control: 125 
 13 pA; baclofen:
204
 27 pA; n 10–9, p 0.015, t test) (Fig. 2D).
GABAB receptors are expressed on both presynaptic and post-
synaptic elements of neurons in the CNS, as well as on glia. We
tested the possibility of a direct postsynaptic link betweenGABAB
receptors and GABAA receptors by intracellular application of
drugs via the patch pipette that modulate GABAB receptor G
protein-coupled signaling pathways. In these experiments we si-
multaneously recorded from four TCneuronswith two cells con-
taining drugs and two drug-free cells to act as internal controls.
By infusing cell-impermeable GDP--S (1 mM) into individual
TC neurons and thus blocking G-protein-mediated signaling in
only that cell, we were able to confirm that GABAB receptor-
dependent enhancement of the tonic current is expressed post-
synaptically. We found that GDP--S completely occluded the
baclofen-induced enhancement in tonic current (baclofen:
118
 27 pA; baclofenGDP: 57
 10 pA; n 12–15, p 0.02,
t test) and, importantly, GDP--S did not reduced the size of the
tonic current recorded in the presence of CGP 55845 (CGP: 41

3 pA; CGP GDP: 43
 6 pA; n 12–14, p 0.9) (Fig. 3A,B).
By continuing to apply drugs intracellularly, we investigated the
pathway by which baclofen enhances the tonic current. Infusion
of pertussis toxin (500 ng/ml) to block all Gi/o-dependent
G-protein signaling also prevented the baclofen-induced en-
hancement in tonic current (baclofen: 100
 15 pA; baclofen
pertussis: 62 
 7 pA; n  16–14, p  0.04, t test) (Fig. 3C).
Pertussis toxin does not block the tonic current directly, as it did
not reduce the amplitude of the tonic current when applied to-
gether with CGP 55845 (CGP) (CGP: 58
 6 pA; CGP pertus-
sis: 52
 7 pA; n 12–14, p 0.5, t test) (Fig. 3D). The inhibitor
of adenylate cyclase, SQ 22536 (SQ) (10M),mimicked the effect
of baclofen and enhanced the tonic current (control: 68
 15 pA;
SQ: 120
 21 pA; n 14–17, p 0.03) (Fig. 3E). Infusion of the
A B
C D
Figure 2. Mechanistic dissection of GABAB receptor-mediated enhancement of tonic inhibition. A, Baclofen does not enhance
the tonic current of TCneurons in slices fromGABAB
/mice.B, Thebaclofen-inducedenhancementof tonic current is dependent
on -containing GABAA receptors, as baclofen has no effect on tonic currents in TC neurons of 
/mice. C, In the presence of
GAT-1 and GAT-3 blockade, baclofen is able to enhance the tonic current recorded in rat TC neurons. D, In the presence of general
potassium channel blockade (2mM Ba 2, 2mM 4-AP, and 10mM TEA), baclofen still enhanced the tonic current recorded in rat TC
neurons.
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active catalytic subunit of protein kinase A (PKA) (10 IU/ml)
was able to block the baclofen-induced enhancement in tonic
current (baclofen: 118 
 21 pA; baclofen  PKA: 27 
 4 pA;
n  12–11, p 	 0.0001) (Fig. 3F ). PKA by itself significantly
reduced the tonic current to a level equivalent to baclofen 
PKA (control: 126 
 32, PKA: 31 
 10; n  10, p  0.002, t
test)(Fig. 3G). Conversely, the PKA inhibitor PKI 14–22 (50
ng/ml) significantly enhanced the tonic current (control: 76

10 pA; PKI: 114
 11 pA; n 15–10, p 0.01, t test) (Fig. 3H ).
Having defined a mechanistic pathway for the modulation of
GABAA receptors by GABAB receptors, we next investigated how
this modulation of tonic inhibition altered the excitability of TC
neurons. To avoid complications arising from modulation of
GIRKs and voltage-gated Ca2 channels that would result from
pharmacological activation of GABAB receptors, we addressed
this problem by using the dynamic clamp technique. TC neurons
were patched and depolarized by current
injection to approximately 55 mV, and
thereafter the level of holding current was
not changed. We then injected excitatory
postsynaptic conductances and measured
the probability of action potential genera-
tion, thus creating an input/output (I/O)
curve. To accurately mimic the tonic cur-
rent with dynamic clamp, we needed to
know its reversal potential. Thus, we
performed gramicidin-perforated patch
recordings and applied a slow voltage
ramp between 70 and 30 mV. Then
we applied gabazine and performed the
ramp again. The difference in the trans-
membrane current between these two
ramps gave us the I/V relationship of the
tonic current (Fig. 4). We found that the
average reversal potential was 76 
 2
mV (n 4; in line with previously pub-
lished values; Ulrich and Huguenard,
1997). As described, TC neurons had a
mean tonic current of 104 pA, and in the
presence of baclofen this increased to
160 pA; thus, the basal tonic conduc-
tance was set to 1.4 nS, and to mimic the
effect of baclofen it was set to 2.0 nS. The
model of the tonic conductance was
noisy and had spectral characteristics to
match those seen in vitro (see Materials
and Methods). The addition of gabazine
(100 M) shifted the I/O curve to the
left by 1.2 nS, in line with the measured
tonic GABAA conductance of 1.4 nS
(Fig. 4A,C). By injecting this conduc-
tance, we almost perfectly recapitulated
the control condition (control: EG50 
11.9 
 1.3 nS; slope  0.34 
 0.01;
dynamic clamp tonic conductance,
EG50  11.7 
 1.2 nS; slope  0.41 

0.02; n  6). We then increased the
tonic conductance to 2.0 nS to repro-
duce the baclofen-induced enhance-
ment of the GABAA system. This
significantly shifted the I/O curve to the
right by 0.32 
 0.2 nS (p 	 0.001), but
had no effect on the slope (0.38 
 0.02;
p  0.3) (Fig. 4C). Thus, by mimicking the effect of baclofen
on the tonic current, both in terms of increasing the magni-
tude of the conductance as well as the power of its noise, we
were able to significantly alter the excitability of TC neurons.
Discussion
The tonic GABAA current is observed across a range of neuronal
cell types and has been implicated in a number of physiological
and pathophysiological roles, including regulation of synaptic
integration andmodulation of anxiety-related behaviors and as a
necessary factor in the expression of spike and wave discharges
associated with typical absence epilepsy (Chadderton et al., 2004;
Maguire et al., 2005; Cope et al., 2009).Herewe show thatGABAB
receptors are able to modulate the -subunit-containing GABAA
receptors responsible for generating this crucial tonic current in
three important cell types, namely TC, DGGC, and CGC. More-
Figure 3. Recordings from TC neurons shows that baclofen enhances tonic GABAA-mediated currents through a Gi/o G-protein,
adenylate cyclase, and PKA-dependent pathway. A, Blockade of all G-protein signaling with GDP--S (1 mM) prevented the
baclofen-induced enhancement in tonic current.B, GDP--S (1mM) does not block the tonic current directly, as in the presence of
CGP 55845 (1M) GDP--S has no effect on the magnitude of the tonic current. C, Blocking all Gi-dependent G-protein signaling
with pertussis toxin (500 ng/ml) prevented the baclofen-induced enhancement in tonic current. D, Pertussis toxin does not block
the tonic current directly, as it did not reduce the amplitude of the tonic current when applied together with CGP 55845 (1M). E,
The inhibitor of adenylate, cyclase SQ 22536 (10M), mimicked the effect of baclofen and enhanced the tonic current. F, Infusion
of theactive catalytic subunit of PKA (10 IU/ml) blocked theenhancementof the tonic current causedbybaclofen.G, PKA (10 IU/ml)
significantly reduced the tonic current. H, The PKA inhibitor PKI 14-22 (50 ng/ml) mimicked the effect of baclofen and produced
significant enhancement of GABAA receptor-mediated tonic current.
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over, our data indicate that GABAB
receptor-mediated enhancement of the
tonic current is sufficient to significantly
alter the excitability of TC cells, showing
that this source of modulation can be of
functional importance for the electrical
behavior of TC neurons. We are able to
rule out that this effect is due to an altera-
tion in the presynaptic release ofGABA, as
the GABAB receptor-mediated enhance-
ment of tonic current could be blocked or
mimicked by infusing drugs solely into
the postsynaptic cell. Likewise, the en-
hancement of tonic current is not due to
GABAB receptors reducing the uptake of
GABA or altering potassium channel
function, as baclofen still enhanced the
tonic current in the presence of GAT and
potassium channel blockade. This modu-
lation appears to be selective for extrasyn-
aptic GABAA receptors, as the amplitude
and kinetics of mIPSCs are not affected by
GABAB receptor activation. Thus, GABAB
receptors are capable of enhancing the ac-
tion of extrasynaptic GABAA receptors
via a G protein-mediated postsynaptic
mechanism.
There is a significant body of literature
showing that PKA can phosphorylate 1
and 3 subunits of the GABAA receptor and that phosphoryla-
tion at the 3 subunit enhances GABAA function, phosphoryla-
tion at the 1 subunit inhibits it, and the 2 subunit is not
affected by PKAmodulation (McDonald et al., 1998; Brandon et
al., 2003; Tang et al., 2010). It is hard to conclude which  sub-
units are responsible for the tonic current inTCneurons. It seems
clear that themajor species is2, due to the sensitivity of thalamic
tonic currents to etomidate and the reduction in the size of tonic
currents in 2/ mice. It is often concluded that as tonic cur-
rents are still enhanced (albeit weakly) by etomidate in mice with
the etomidate-insensitive 2 mutation 2N265S, this indicates
that 3 subunits are responsible for the rest of the tonic current
(Belelli et al., 2005). However, it is worth noting that 1 subunits
appear to be sensitive to the concentration of etomidate (3 M)
used by Belelli et al., (2005) (Hill-Venning et al., 1997). While
some evidence shows a paucity of 1 subunit expression in the
VB thalamus (Wisden et al., 1992), other reports indicate that it is
expressed in significant amounts (albeit less than2) (Huntsman
et al., 1996; Pirker et al., 2000). If we assume that the PKA sensi-
tivity of  subunits mentioned above is true across all subunit
combinations, then our results indicate that 41 make up a
significant fraction of extrasynaptic receptors. The other inter-
pretation is that 42 may indeed be sensitive to negative-
modulation by PKA. In DGGCs, it seems likely that the tonic
current is mediated by mainly a mix of 1- and 2-containing
GABAA receptors, and hence our results are easy to reconcile with
the molecular makeup of these receptors (Mtchedlishvili and
Kapur, 2006; Herd et al., 2008). The mRNA for all  subunits is
expressed by cerebellar granule cells, but we are not aware of any
studies showing which  subunits are responsible for the tonic
current in CGCs (Laurie et al., 1992). Hence, we believe it is likely
that across these three different cell types, GABAB receptor acti-
vation enhances tonic GABAA receptor function by inhibiting
cAMPand reducing the inhibitory effect of PKAat1-containing
GABAA receptors. Thismaymean that PKA could act to integrate
the signaling ofmanyG protein-coupled receptors andmodulate
cellular excitability in neurons expressing a tonicGABAA current.
Indeed, it has been shown previously that dopamine can modu-
late the excitability of medium spiny neurons via a PKA-
dependent modulation of the tonic GABAA current (Janssen et
al., 2009). However, it is also possible that there are other regula-
tory proteins downstream of PKA that mediated the GABAB
receptor-mediated enhancement of tonic GABAA currents,
rather than PKA phosphorylating extrasynaptic GABAA recep-
tors directly.
In conclusion, our results show for the first time, a functional
postsynaptic crosstalk between GABAB and GABAA receptors.
They also raise the intriguing possibility that several of baclofen’s
clinical actions could be, at least in part, due to the GABAB-
mediated enhancement of tonic GABAA currents throughout the
brain. The most obvious of these is baclofen’s use in ethanol
dependence and withdrawal because of ethanol’s ability to en-
hance the tonic GABAA current (Wei et al., 2004; Addolorato et
al., 2007).
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